Craft
Lyell

Lyell

Revenue

$10.7 M

FY, 2021

Market Capitalization

$1.7 B

2022-09-21

Lyell Summary

Company summary

Overview
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors. Its technologies are designed to be applied in a target and modality agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL), and T cell receptor (TCR) therapies. The company develops Gen-R and Epi-R technology platforms to develop a multi-modality product.
Type
Public
Founded
2018
HQ
South San Francisco, CA, US | view all locations
Website
https://lyell.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Liz Homans

    Liz Homans, Chief Executive Officer

  • Richard Goold

    Richard Goold, Chief Information Officer

  • Stephen Hill

    Stephen Hill, Chief Technical Operations Officer

  • Lisa Ryan

LocationsView all

3 locations detected

  • South San Francisco, CA HQ

    United States

    201 Haskins Way

  • Bothell, WA

    United States

    2525 223rd St SE

  • Seattle, WA

    United States

    500 Fairview Ave N #560

Lyell Financials

Summary financials

Revenue (Q2, 2022)
$35.7M
Net income (Q2, 2022)
($36.3M)
Cash (Q2, 2022)
$205.7M
EBIT (Q2, 2022)
($37.3M)
Enterprise value
$1.6B

Footer menu